CSPC Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	-	6,090	6,777	12,015	10,298	9,284
Short-Term Investments	-	4,283	2,360	1,750	4,268	2,024
Cash & Short-Term Investments	10,373	10,373	9,137	13,765	14,566	11,307
Cash Growth	13.52%	13.52%	-33.62%	-5.50%	28.82%	21.38%
Accounts Receivable	-	8,694	9,542	9,712	6,736	6,508
Other Receivables	-	92.55	79.18	129.65	100.05	39.78
Receivables	-	8,787	9,621	9,841	6,836	6,549
Inventory	-	3,091	3,130	3,139	2,555	2,480
Total Current Assets	-	22,251	21,888	26,745	23,957	20,337
Property, Plant & Equipment	-	13,489	12,503	11,643	10,977	9,564
Long-Term Investments	-	7,109	6,271	4,596	3,720	3,323
Goodwill	-	234.9	234.9	234.9	234.9	149.98
Other Intangible Assets	-	2,658	2,518	2,146	1,872	425.87
Long-Term Deferred Tax Assets	-	211.51	250.3	186.78	113.03	43
Long-Term Deferred Charges	-	116.92	91.8	52.53	35.81	41.98
Other Long-Term Assets	-	628.05	632.23	678.51	859.31	857.51
Total Assets	-	46,698	44,389	46,282	41,770	34,742
Accounts Payable	-	3,409	2,988	2,889	2,206	1,770
Accrued Expenses	-	3,613	3,821	-	3,922	3,166
Short-Term Debt	-	307.72	364.2	441.27	145.64	-
Current Portion of Long-Term Debt	-	21	28	8.95	7.84	-
Current Portion of Leases	-	131.69	58.99	149.63	142.07	38.42
Current Income Taxes Payable	-	229.13	137.51	379.45	261.61	260.73
Current Unearned Revenue	-	896.2	538.05	494.9	940.5	645.75
Other Current Liabilities	-	1,570	1,697	5,820	1,333	1,346
Total Current Liabilities	-	10,178	9,634	10,183	8,958	7,226
Long-Term Debt	-	-	-	-	28.95	-
Long-Term Leases	-	180.69	56.14	107.06	258.04	55.62
Long-Term Unearned Revenue	-	1,414	407.81	340.53	270.92	250.2
Long-Term Deferred Tax Liabilities	-	374.86	424.73	574.84	611.99	381.48
Other Long-Term Liabilities	-	-	-	59.16	-	-
Total Liabilities	-	12,148	10,523	11,264	10,128	7,913
Common Stock	-	11,061	11,033	10,899	10,899	10,899
Additional Paid-In Capital	-	511.55	588.85	390.53	196.57	46.79
Retained Earnings	-	26,871	25,650	26,245	23,192	19,188
Treasury Stock	-	-752.85	-612.04	-316.21	-83.71	-85.6
Comprehensive Income & Other	-	-4,513	-4,394	-4,015	-4,006	-4,062
Total Common Equity	33,178	33,178	32,265	33,203	30,198	25,987
Minority Interest	-	1,372	1,602	1,815	1,444	841.56
Shareholders' Equity	34,550	34,550	33,866	35,018	31,642	26,828
Total Liabilities & Equity	-	46,698	44,389	46,282	41,770	34,742
Total Debt	641.11	641.11	507.33	706.9	582.54	94.04
Net Cash (Debt)	9,732	9,732	8,630	13,058	13,984	11,213
Net Cash Growth	12.77%	12.77%	-33.91%	-6.62%	24.70%	24.61%
Net Cash Per Share	0.85	0.85	0.74	1.10	1.17	0.94
Filing Date Shares Outstanding	11,403	11,422	11,538	11,852	11,917	11,918
Total Common Shares Outstanding	11,403	11,422	11,538	11,852	11,917	11,918
Working Capital	-	12,073	12,254	16,562	14,999	13,110
Book Value Per Share	2.90	2.90	2.80	2.80	2.53	2.18
Tangible Book Value	30,285	30,285	29,512	30,822	28,090	25,411
Tangible Book Value Per Share	2.65	2.65	2.56	2.60	2.36	2.13
Buildings	-	5,955	5,565	5,389	4,639	4,135
Machinery	-	10,549	9,943	9,194	7,317	6,723
Construction In Progress	-	2,918	2,235	1,246	2,245	1,534